Drugdocs | Empliciti

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Empliciti

Chemical Name	elotuzumab
Dosage Form	Injection (intravenous; 300 mg, 400mg)
Drug Class	Monoclonal antibodies
System	Blood
Company	Bristol Myers Squibb
Approval Year	2015

Indication

In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Empliciti (elotuzumab) Prescribing Information	2019	Bristol-Myers Squibb Company, Princeton, NJ

Document Title	Year	Source
A Comparison of the efficacy of immunomodulatory-containing regimens in relapsed/refractory multiple myeloma: a network meta-analysis.	2018	Clinical Lymphoma, Myeloma & Leukemia
Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.	2017	Oncotarget

Document Title	Year	Source
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.	2017	Expert Review of Hematology